January 13th 2013
The next-generation HIV integrase inhibitor dolutegravir worked as well as raltegravir (Isentress), an approved drug in this class, for treatment-naive people in the Phase 3 SPRING-2 trial, according to a report published in the January 8, 2013, advance edition of The Lancet.
Source : The Lancet, hiv&hepatitis,